Kimco Realty Corporation (HC) Common Stock vs Neurocrine Biosciences Inc — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.16 (market cap $14.82B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Kimco Realty Corporation (HC) Common Stock and Neurocrine Biosciences Inc are close in size by market cap, and Kimco Realty Corporation (HC) Common Stock pays a 5.07% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 1 Days and Neurocrine Biosciences Inc for 23 Days on average.
| KIM | NBIX | |
|---|---|---|
Market Cap | $14.82B | $14.36B |
Volume | 5,158,462 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $26.38 | $185.50 |
52-Week Low | $19.78 | $123.10 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $22.98B | $14.37B |
Dividend Yield | 5.07% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.
Read more on KIM →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →